Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/45882
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBozkurt, Biykem-
dc.contributor.authorMULLENS, Wilfried-
dc.contributor.authorLeclercq, Christophe-
dc.contributor.authorRusso, Andrea M.-
dc.contributor.authorSavarese, Gianluigi-
dc.contributor.authorBoehm, Michael-
dc.contributor.authorHill, Loreena-
dc.contributor.authorKinugawa, Koichiro-
dc.contributor.authorSato, Naoki-
dc.contributor.authorAbraham, William T.-
dc.contributor.authorBayes-Genis, Antoni-
dc.contributor.authorMebazaa, Alexandre-
dc.contributor.authorRosano, Giuseppe M. C.-
dc.contributor.authorZieroth, Shelley-
dc.contributor.authorLinde, Cecilia-
dc.contributor.authorButler, Javed-
dc.date.accessioned2025-04-22T09:05:10Z-
dc.date.available2025-04-22T09:05:10Z-
dc.date.issued2025-
dc.date.submitted2025-04-18T11:00:45Z-
dc.identifier.citationEuropean journal of heart failure,-
dc.identifier.urihttp://hdl.handle.net/1942/45882-
dc.description.abstractGuidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision-making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices are frequently referred too late or not at all. Misconceptions about device therapy and the notion that the needs of patients (especially the prevention of sudden cardiac death) can now be met by expanding drug therapies may play a role in these disparities. This state-of-the-art review is produced by members of the DIRECT HF initiative, a patient-centred, expert-led educational programme that aims to advance guideline-directed use of CRM devices in patients with HFrEF. This review discusses the latest evidence on the role of CRM devices in reducing HFrEF mortality and morbidity, and provides practical guidance on patient referral, device selection, implant timing and patient-centred follow-up.-
dc.description.sponsorshipAcknowledgements The DIRECT HF educational programme is coordinated by MedEdGlobal Solutions, Paris, France. Editorial support was provided byJenny Bryan. Funding The DIRECT HF educational programme is supported by Medtronic.Conflict of interest: B.B. has served as consultant or advisory commit-tee member for Abbott, Abiomed/Johnson and Johnson, Bayer, BoehringerIngelheim, Cardurion, Cytokinetics, Eli Lilly, Medtronic, Merck, Idorsia,Novo Nordisk, Regeneron, Renovacor, Roche, Salubris, Sanofi-Aventis,scPharmaceuticals, CSL Vifor, and Zoll Respicardia. W.M. has nothing todisclose. Ch.L. has received consulting and speaker fees from Medtronicand Biotronik. A.M.R. has received research grants from Abbott, BostonScientific, Medtronic; honoraria or consulting fees from Abbott, Biotronik,Boston Scientific, Medtronic, and PaceMate; fellowship support fromMedtronic; and royalties from UptoDate. G.S. has received grants and per-sonal fees from CSL Vifor, Boehringer Ingelheim, AstraZeneca, Servier,Novartis, Cytokinetics, Pharmacosmos, Bayer, and Medtronic; personalfees from Roche, Abbott, Edwards Lifesciences, TEVA, INTAS, Hikma,and Menarini; and grants from Boston Scientific and Merck. M.B. is sup-ported by the Deutsche Forschungsgemeinschaft (German Research Foun-dation) and has received personal fees from Abbott, Amgen, AstraZeneca,Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, Servier,and CSL Vifor. L.H. has received speaker fees from AstraZeneca, CSLVifor, and Medtronic. K.K. has received consulting fees from Otsuka,Abiomed, Novartis, Medtronic, Boehringer Ingelheim, Abbott and Bayer;speaker fees from Otsuka, Abiomed, Novartis, Medtronic, BoehringerIngelheim, Abbott, Daiichi-Sankyo, Alnylam, Nipro, AstraZeneca, Ono, and Bayer; writing fees from Otsuka; research support from Ono, Kowa, andBoehringer Ingelheim; and scholarship funds from Otsuka and Ono. N.S.has received speaker and consulting fees from Otsuka, Novartis, BMS,Bayer, Terumo, Boehringer Ingelheim, Daiichi-Sankyo, Ono, Medtronic,AstraZeneca, Taisho, and Kowa. W.T.A. has received consulting or speakerfees from Boehringer Ingelheim, CVRx, Impulse Dynamics, Medtronic,Sensible Medical, Vectorious, V-Wave, and Zoll Respicardia. A.B.G. hasreceived speaker or consulting fees from Abbott, AstraZeneca, Bayer,Boehringer Ingelheim, Medtronic, Novartis, Novo Nordisk, Roche Diag-nostics, and CSL Vifor. A.M. has received research grants from Roche,4TEEN4, Sphyngotec, Abbott Diagnostics, and Windtree; consulting feesfrom Roche, Adrenomed, Corteria, and Fire1; speaker honoraria fromMerck, Novartis, Roche, and Bayer; and lab supplies by Sphyngotec; andis an advisory board member for Secret-HF, S-Form Pharma, and Implic-ity. G.M.C.R. has received grants and personal fees from AstraZeneca,Boehringer Ingelheim, Medtronic, Novartis, and CSL Vifor; and has receivedgrants from Bayer, Cytokinetics, Menarini, and Servier. S.Z. has receivedresearch grant support, served on advisory boards for, or had speakerengagements with Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim,CSL Vifor, Cytokinetics, Edwards, Eli Lilly, GSK, Medtronic, Merck, Novar-tis, Novo Nordisk, and Pfizer; serves on a clinical trial committee for studiessponsored by AstraZeneca, Boehringer Ingelheim, Cytokinetics, Merck,Novartis, Pfizer, Salubris Bio; and has received non-industry fees fromCanadian Medical and Surgical KT Group, CCS, CHFS, Charité, EOCI, Liv,Medscape, Ology, PACE-CME, Radcliffe, Reach MD, Translational MedicineAcademy, and Voxmedia. Ce.L. has received research grants from theSwedish Heart Lung Foundation, the Swedish Council of Science, and theStockholm County Council. J.B. has received consulting fees from Abbott,Adaptyx, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas,AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol MyersSquibb, Cardiac Dimension, Cardior, CSL Behring, CVRx, Cytokinetics,Edwards, Element Science, Faraday, Foundry, Innolife, Impulse Dynamics,Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronic, Merck,Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Phar-maIN, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SCPharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics,Vifor, and Zoll-
dc.language.isoen-
dc.publisherWILEY-
dc.rights2025 European Society of Cardiology.-
dc.subject.otherPatient-centred heart failure care-
dc.subject.otherSudden cardiac death-
dc.subject.otherCardiac dyssynchrony-
dc.subject.otherCardiac implantable electronic device-
dc.subject.otherImplantable cardioverter-defibrillator-
dc.subject.otherCardiac resynchronization therapy-
dc.titleCardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document-
dc.typeJournal Contribution-
local.format.pages20-
local.bibliographicCitation.jcatA1-
dc.description.notesBozkurt, B (corresponding author), Cardiovasc Res Inst, Winters Ctr Heart Failure, 1 Baylor Pl, Houston, TX 77030 USA.-
dc.description.notesbbozkurt@bcm.edu-
local.publisher.place111 RIVER ST, HOBOKEN 07030-5774, NJ USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.statusEarly view-
dc.identifier.doi10.1002/ejhf.3641-
dc.identifier.pmid40204670-
dc.identifier.isi001462248600001-
local.provider.typewosris-
local.description.affiliation[Bozkurt, Biykem] Baylor Coll Med, Houston, TX USA.-
local.description.affiliation[Mullens, Wilfried] Ziekenhuis Oost Limburg, Genk, Belgium.-
local.description.affiliation[Mullens, Wilfried] Hasselt Univ, Hasselt, Belgium.-
local.description.affiliation[Leclercq, Christophe] Univ Rennes, Rennes, France.-
local.description.affiliation[Russo, Andrea M.] Rowan Univ, Cooper Med Sch, Camden, NJ USA.-
local.description.affiliation[Savarese, Gianluigi; Linde, Cecilia] Karolinska Inst, Stockholm, Sweden.-
local.description.affiliation[Boehm, Michael] Saarland Univ, Homburg, Germany.-
local.description.affiliation[Hill, Loreena] Queens Univ Belfast, Belfast, North Ireland.-
local.description.affiliation[Kinugawa, Koichiro] Univ Toyama, Toyama, Japan.-
local.description.affiliation[Sato, Naoki] Kawaguchi Cardiovasc & Resp Hosp, Saitama, Japan.-
local.description.affiliation[Abraham, William T.] Ohio State Univ, Sch Med, Columbus, OH USA.-
local.description.affiliation[Bayes-Genis, Antoni] Autonomous Univ Barcelona, CIBERCV, Barcelona, Spain.-
local.description.affiliation[Mebazaa, Alexandre] Univ Paris Cite, MASCOT, APHP, Inserm Unit, Paris, France.-
local.description.affiliation[Rosano, Giuseppe M. C.] San Raffaele Open Univ Rome, Dept Human Sci & Promot Qual Life, Rome, Italy.-
local.description.affiliation[Rosano, Giuseppe M. C.] San Raffaele Cassino Hosp, Cardiol, Cassino, Italy.-
local.description.affiliation[Rosano, Giuseppe M. C.] IRCCS San Raffaele Roma, Rome, Italy.-
local.description.affiliation[Rosano, Giuseppe M. C.] City St Georges Univ London, Mol & Clin Sci Res Inst, Cardiol Clin Acad Grp, London, England.-
local.description.affiliation[Zieroth, Shelley] Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada.-
local.description.affiliation[Butler, Javed] Baylor Scott & White Res Inst, Dallas, TX USA.-
local.description.affiliation[Butler, Javed] Univ Mississippi, Jackson, MS USA.-
local.uhasselt.internationalyes-
item.accessRightsOpen Access-
item.fullcitationBozkurt, Biykem; MULLENS, Wilfried; Leclercq, Christophe; Russo, Andrea M.; Savarese, Gianluigi; Boehm, Michael; Hill, Loreena; Kinugawa, Koichiro; Sato, Naoki; Abraham, William T.; Bayes-Genis, Antoni; Mebazaa, Alexandre; Rosano, Giuseppe M. C.; Zieroth, Shelley; Linde, Cecilia & Butler, Javed (2025) Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document. In: European journal of heart failure,.-
item.fulltextWith Fulltext-
item.contributorBozkurt, Biykem-
item.contributorMULLENS, Wilfried-
item.contributorLeclercq, Christophe-
item.contributorRusso, Andrea M.-
item.contributorSavarese, Gianluigi-
item.contributorBoehm, Michael-
item.contributorHill, Loreena-
item.contributorKinugawa, Koichiro-
item.contributorSato, Naoki-
item.contributorAbraham, William T.-
item.contributorBayes-Genis, Antoni-
item.contributorMebazaa, Alexandre-
item.contributorRosano, Giuseppe M. C.-
item.contributorZieroth, Shelley-
item.contributorLinde, Cecilia-
item.contributorButler, Javed-
crisitem.journal.issn1388-9842-
crisitem.journal.eissn1879-0844-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
European J of Heart Fail - 2025 - Bozkurt - Cardiac rhythm devices in heart failure with reduced ejection fraction role .pdfEarly view8.18 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.